CYMS101
Multiple Sclerosis (MS)
PreclinicalActive
Key Facts
About FibroBiologics
FibroBiologics is a clinical-stage biotech focused on developing fibroblast cell-based therapies for chronic diseases, positioning fibroblasts as a superior alternative to mesenchymal stem cells. The company has established a robust intellectual property portfolio of over 270 patents and has achieved an FDA IND clearance for its lead program in Degenerative Disc Disease. Its strategy hinges on demonstrating clinical proof-of-concept for its fibroblast platform across multiple high-need indications to validate its core technological thesis and unlock significant value.
View full company profileTherapeutic Areas
Other Multiple Sclerosis (MS) Drugs
| Drug | Company | Phase |
|---|---|---|
| Alpha-Cobratoxin (Pharmaceutical) | Nutra Pharma | Preclinical |
| CNM-Au8 | Clene | Phase 2 |
| Sequential Dialysis Technique | Halberd | Discovery |
| MS Treatment (with Cycle Vita) | Cycle Pharmaceuticals | Commercial |
| GM6 | Genervon Biopharmaceuticals | Planning |
| MS Biomarker Development | Progentec Diagnostics | Pre-clinical/R&D |
| Next-Gen CAR-Tregs | PolTREG | Preclinical |
| XT-150 (Preclinical) | Xalud Therapeutics | Preclinical |
| MEK Inhibitor Program | Pasithea Therapeutics | Discovery |